31/05/2026 Johnson & Johnson submits US sBLA for subcutaneous amivantamab in HPV-unrelated R/M HNSCC, previously treated with immunotherapy and chemotherapy Johnson & Johnson submits US sBLA for subcutaneous amivantamab in HPV-unrelated R/M HNSCC, previously treated with immunotherapy and chemotherapy (Ref) Johnson & Johnson confirmed that a supplemental Biologics License Application (sBLA) has been submitted to the US FDA seeking approval of subcutaneous amivantamab (EGFR x

April 2nd Week, 2025 Regulatory Events 🎯 AstraZeneca and Daiichi Sankyo ’s trastuzumab deruxtecan (HER2 ADC) mono has been approved...

March 4th Week, 2025 Regulatory Events 🎯 CStone Pharmaceuticals submitted a Type II variation application to the EMA for sugemalimab...

March 2nd Week, 2025 Mergers & Acquisitions 🤝 Checkpoint Therapeutics Inc is set to be acquired by SUN PHARMA , an Indian pharma...